Risk-Based Fraud Detection: How Centralized Monitoring Can Boost Data Quality

March 24, 2022 — March 24, 2022

This webinar presented the results of a new study that further demonstrated that risk-based monitoring is an efficient tool to detect fraud at clinical trial sites and early identify data quality and safety issues in clinical trials

ABSTRACT

This webinar presents the results of a new study that further demonstrated that risk-based monitoring is an efficient tool to detect fraud at clinical trial sites and early identify data quality and safety issues in clinical trials.

More than 7,000 patients across 60 sites and 13 countries took part in the Second European Stroke Prevention Study (ESPS2) in the early 1990s. The international, multisite, randomized, double-blind trial compared acetylsalicylic acid and/or dipyridamole to matching placebos to prevent stroke or death in patients with pre-existing ischemic cerebrovascular disease. Severe inconsistencies in the case report forms (CRF) at one site led the trial’s steering committee to question the data’s reliability. A for-cause analysis of quality control samples and extensive additional analyses, including blood concentrations of the investigational drugs, showed the patients had never received the protocol medications.

CluePoints’ advanced SMARTTM engine, a set of advanced statistical methods, was applied to the completed study to identify unusual patterns at sites. The CluePoints data analyst performing the analysis reminded blinded regarding the site that committed fraud. The SMARTTM engine was able to detect the fraudulent site by applying an unsupervised analysis to all clinical variables. The fraudulent site ranked second among all sites demonstrating the power of applying central statistical monitoring to detect fraud at site.

KEY TAKEAWAYS

  • Central Statistical Monitoring is an efficient tool to monitor clinical trials and identify quality and safety issues at sites
  • In extreme cases, Central Statistical Monitoring is an efficient tool to unreveal fraud at site

DOWNLOAD PRESENTATION 

SPEAKERS

Laura Trotta, Vice President of Research, CluePoints

Dr Laura Trotta joined CluePoints in 2015 and moved into her current role as Vice President of Research in January 2022, where she leads a team of research scientists responsible for developing new statistical and machine learning algorithms to assess the quality of clinical trial data. Laura holds a Master’s degree in Biomedical Engineering and a PhD in Applied Mathematics from the University of Liège, Belgium.

Sylviane de Viron, Data and Knowledge Manager, Cluepoints

As Data and Knowledge Manager, Sylviane is responsible for creating knowledge on risk-based quality management (RBQM) using CluePoints accumulated data.

Sylviane worked for the last 12 years in the medical and pharmaceutical sector in various positions. Sylviane holds a PhD in Public Health from Maastricht University.

Presentation Webinar : Risk-Based Fraud Detection: How Centralized Monitoring Can Boost Data Quality

Please fill in the form to access the presentation of the webinar.

    By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

    I authorize IDDI to use my data to contact me for commercial purposes. More information